Summary The relationship between negative cervical cytology reports and risk of adenocarcinoma of the cervix was evaluated in a case-control study of 113 cases and 452 controls. All cases and controls had received at least two negative cytology reports. There was no significant difference between the cases and controls in the number of negative cytology reports or in history of cervical abnormality; while a test for trend in the time since last negative cytology report was significant (P<0.001), the estimated benefit was very modest. Although the estimates of relative protection were higher in women aged less than 35 years than in women aged (Brinton et al., 1987; Parazzini et al., 1988).
The incidence of adenocarcinoma of the cervix among women aged less than 35 years more than doubled between the late 1960s/early 1970s and the early 1980s (Peters et al., 1986; Schwartz and Weiss, 1986; Chilvers et al., 1987) . The reasons for this increase are poorly understood. While one case series has documented a higher prevalence of oral contraceptive use among women with adenocarcinoma (Dallengach-Hellweg, 1984) , other studies have found no evidence of different oral contraceptive use between women with adenocarcinoma and women with squamous malignancy (Silcocks et al., 1987) on between women with adenocarcinoma and control women (Brinton et al., 1987; Parazzini et al., 1988) .
Case-control studies have become an established method of evaluating screening programmes. The degree to which adenocarcinoma of the cervix can be prevented by cervical cytology screening has not been well defined. While some published case-control studies have included adenocarcinoma cases in their series (Clarke and Anderson, 1979; La Vecchia et al., 1984; Brinton et al., 1987; Olesen, 1988; Celentano et al., 1989; Shy et al., 1989; Cohen, 1993) , the cases have been few in number, constituting only a small minority of all cases. One study of 40 patients with adenocarcinomai found no significant difference in self-reported screening history between cases and controls (Brinton et al., 1987) . No validation of the screening history was undertaken, and it appears that the time interval since the last negative Papanicolaou smear report was not specifically sought. Three studies have commented that Papanicolaou smear screening appears to be less effective for the prevention of adenocarcinoma than for squamous carcinoma but have not provided separate analyses for adenocarcinoma (Clarke and Anderson, 1979; Olesen, 1988; Shy et al., 1989) .
We undertook a case-control study to evaluate the duration of low risk for adenocarcinoma of the cervix after negative cervical cytology results. Cases were diagnosed mainly in the 1980s when screening was well established in Australia. Adenocarcinoma of the cervix constituted 13% of all cervical malignancies at the time of the study (Giles et al., 1992 Conditional logistic regression revealed that none of the three variables (time since last negative smear, number of negative smears or history of abnormality) was significantly different between cases and controls (see Table I ). The relationship with time since the last negative cytology report was variable. When the last negative cytology report was within 2 years of the exit date, some degree of protection was evident although it did not reach statistical significance. However, Adenocardnoma risk H Mitchell et al 895 when the last negative cytology report was between 2 and 10 years before the exit date, there was no evidence of protection. A test for trend in increasing relative protection by time since last negative smear was significant (P<0.001). However, the estimated relative protections were not greater than 1 except where the time period since last negative smear wasless than 2 years. Further, the largest relative protection of 1.6 corresponds to a very modest benefit, particularly in comparison with benefits for squamous cancer. The test for trend in relative protection by number of negative smears was not significant (P = 0.8).
There was no evidence of a modifying effect of age on the risk of adenocarcinoma after negative cytology (test for effect modification, P = 0.4). However, the pattern of relative protection estimates differed between the two age groups (see Table II ). Because of the small numbers of women involved, the baseline for this analysis was taken as last negative cytology report 6 or more years before the exit date. For younger women, relative protection declined from 11.1 during the first year and 7.8 during the second year to 3.8 when the last negative cytology report was between 3 and 6 years before the exit date. There was no clear relationship between relative protection estimates and time since last negative cytology report among older women.
The median time interval between negative cytology reports was 1.9 years for younger cases compared with 2.0 years for their controls. Older women were screened marginally less frequently with the median time interval between negative cytology reports being 2.1 years for both cases and controls. Thus, while the median time between negative smears was similar for cases and controls, the timing of the smears in relation to the exit date differed. This large study found little difference in the screening histories of women with adenocarcinoma of the cervix compared with control women. This result confirms the findings of Brinton's smaller study (1987) . This is very different to studies of women with squamous cancer of the cervix, which have all found significant underscreening of women compared with controls for at least 3 years before diagnosis of cancer (Clarke and Anderson, 1979; La Vecchia et al., 1984; MacGregor et al., 1985; Brinton et al., 1987; Olesen, 1988; van der Graaf et al., 1988; Celentano et al., 1989; Shy et al., 1989; Cohen, 1993) . A large metaanalysis found underscreening for 6 years (IARC Working Group, 1986) . This meta-analysis involved 162 cases of squamous cancer among women with two or more negative cytology reports recruited from seven geographic areas over periods ranging from 11 to 23 years. Our study of 113 cases drawn from one geographic area over an 11 year period is therefore of substantial size; it had 88% power to detect a halving in the risk of cancer within 3 years of a negative cytology report at the 0.05 significance interval. Cases were selected from Cancer Registry and laboratory files. This study did not involve any personal contact with women, and this has meant that no bias has been introduced as a result of only survivors or women in comparatively good health being available for interview. Controls were selected from laboratory records and therefore represent the same population of screened women from which cases were drawn. Entry to the study required evidence that the control women were still at risk of cervical cancer on or around the exit date. Given the high hysterectomy rate among older women, failure to do this would have produced artificially low screening rates among control women. Overall, 57% of the control women in this study were screened within 2 years of the exit date; in comparison, 50% of Australian women aged 20-69 years were screened during the 2 year period, -89 (Australian Health Ministers, 1991 . Thus, the stringent requirements for eligibility as a control in this study have possibly overestimated the screening history of control women, increasing the estimates of relative protection.
Because the screening histories of both cases and controls were compiled from laboratory records, this study has avoided recall and reporting bias. It has been shown repeatedly that women overestimate their screening history and are not able to distinguish reliably between having a smear and receiving a negative smear result (Walter et al., 1988; Sawyer et al., 1989; Boyce et al., 1990; Bowman et al., 1991) . This study has not been able to adjust for other risk factors for adenocarcinoma of the cervix. However these are poorly defined, with published literature comprising two case-control studies (Brinton et al., 1987; Parazzini et al., 1988) . The only risk factor common to both studies was being overweight, a variable which is unlikely to be associated with screening.
While the estimates of relative protection differed between the two age groups, the differences did not reach statistical significance. The suggestion that screening may be beneficial for up to 2 years in younger women but not in older women could reflect easier sampling of glandular cells in younger women whose transformation zone is located closer to the cervical os. The laboratory has never had an age differential in its policy of provision of sampling instruments (such as cytobrushes) specifically designed to sample from the endocervical canal. Since 1989 when such instruments were routinely provided to all doctors, sufficient supplies have been made available for each doctor to use them regardless of the age of the woman.
This study is unable to evaluate completely the benefits of screening as it focused on screened women who developed invasive cancer. It is possible that some adenocarcinomas were prevented by detection of precancerous abnormalities. The possible benefit could be clarified by a case-control study that compared the screening histories of all women diagnosed with adenocarcinoma with a control group selected from the community, with case and control selection not requiring participation in screening as an eligibility criterion.
Nevertheless, we believe that adenocarcinoma among screened women is a problem of considerable magnitude. We were able to detect 113 cases of adenocarcinoma which had occurred among screened women; a parallel study of squamous cancer which we are conducting over the same time period has been able to detect 220 cases (53 younger, 167 older women). This ratio of approximately two squamous to one adenocarcinoma is very different to the ratio of 20 squamous to one adenocarcinoma which occurred before screening reduced the incidence of squamous cancer (Rombaut et al., 1966; Anderson and Fraser, 1976; Hurt et al., 1977) .
On a more optimistic note, it is possible that better detection of precancerous glandular abnormalities will have occurred since 1989 when endocervical brushes were introduced into routine use. Our case-control study primarily reflects the quality of cervical screening before this time. Columnar cells from the endocervix are now reported in 80% of smears compared with only 50% before the introduction of endocervical brushes (Mitchell and Medley, 1993) . However, reports of precancerous endocervical disease remain quite rare, constituting fewer than 1 in 5000 cytology reports (Victorian Cervical Cytology Registry, 1993) . Further studies in this area are warranted, particularly given the increasing incidence of adenocarcinoma in young women.
